Trial Profile

A global Phase 3 trial assessing Teverelix® in advanced prostate cancer patients with increased CV risk

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 14 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Teverelix (Primary)
Indications Prostate cancer
Focus Registrational; Therapeutic Use

Most Recent Events

14 Mar 2023 New trial record
08 Mar 2023 According to Antev media release, US Food & Drug Administration (FDA) has provided written guidance on the companys proposed Phase 3 pivotal trial design; top-line results expected in 2027

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com